Dr Steven Schmitt is CEO of Myria Biosciences.
Myria Biosciences is spearheading a groundbreaking approach to drug discovery, leveraging the fusion of synthetic biology and artificial intelligence to engineer transformative therapies.
The company strives to understand how evolution has enabled nature to create complex chemical compounds and to utilize this knowledge to redesign nature.
The company envisions synthetic organisms that are designed at will and with the ability to produce highly complex and entirely new “synthetic natural products”. Producing novel chemical matter at scale, Myria can provide tailored and strcuturally complex chemical compounds to adress unmet medical needs.